

The Use of the Electromotive Drug Administration System in Patients With Superficial Bladder Cancer: A Review

Context

Superficial bladder cancer refers to the growth of cancer cells in the lining of the bladder wall but not in the bladder muscle. In 2008, this type of cancer accounted for about 6% of all cancers in Canada. Systemic drug delivery — releasing a drug into the bloodstream — is generally ineffective in treating this condition because the bladder wall prevents drugs from diffusing into the bladder. Intravesical drug delivery — delivering a drug through a catheter directly into the bladder — is more effective but has several limitations, such as the need for repeated infusions. A high recurrence rate coupled with the need for repeated treatments make bladder cancer a costly cancer to treat.

Technology

A new, potential option for treating superficial bladder cancer is electromotive drug administration (EMDA), which delivers drug therapy intravesically using an electrical current. EMDA may also be a cost-effective alternative to the traditional intravesical method. Canadian guidelines on the treatment of bladder cancer issued in 2010 did not provide recommendations for EMDA because there was a lack of evidence at that time.

Issue

A review of the evidence on the efficacy, safety, and cost-effectiveness of EMDA for superficial bladder cancer will help to inform treatment decisions for patients with this condition.

Methods

A limited literature search was conducted of key resources, and titles and abstracts of the retrieved publications were reviewed. Full-text publications were evaluated for final article selection according to predetermined selection criteria (population, intervention, comparator, outcomes, and study designs).

Key Messages

For the treatment of superficial bladder cancer:

- Using EMDA to administer mitomycin before performing transurethral resection of the bladder tumour (TURBT) to surgically remove the tumour may be more effective and result in fewer adverse effects than traditional intravesical drug administration of mitomycin after TURBT or than TURBT alone (based on only one study).
- No information was found on the cost-effectiveness of EMDA.

Results

The literature search identified 46 citations, with 7 additional articles identified from other sources. After screening the abstracts, 1 study — a randomized controlled study — met the criteria for inclusion in this review.

DISCLAIMER: The information in this Report in Brief is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this Report in Brief should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the Report in Brief to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this Report in Brief.

CADTH takes sole responsibility for the final form and content of this Report in Brief. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government. Production of this Report in Brief is made possible through a financial contribution from Health Canada.